Muscle News and Research

RSS

University of Adelaide research focuses on techniques to treat swallowing disorders

A simple function that most of us take for granted - swallowing - is the focus of University of Adelaide research which could help thousands of stroke sufferers around the world.

12 Sep 2011

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking sales and marketing approval for vismodegib to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC for whom surgery is inappropriate.

12 Sep 2011

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

12 Sep 2011

Researchers discover that recognisable facial expressions develop before birth

Babies in the womb develop a range of facial movements in such a way that it is possible to identify facial expressions such as laughter and crying. For the first time a group of researchers were able to show that recognisable facial expressions develop before birth and that, as the pregnancy progresses from 24 to 36 weeks gestation, fetal facial movements become more complex.

12 Sep 2011

New treatment strategy for dominant forms of muscular dystrophy

Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.

12 Sep 2011

Researchers describe new function of HCN channels in the heart

The heartbeat is the result of rhythmic contractions of the heart muscle, which are in turn regulated by electrical signals called action potentials. Action potentials result from the controlled flow of ions into heart muscle cells (depolarization) through channels in their membranes, and are followed by a compensating reverse ion current (repolarization), which restores the original state. If the duration of the repolarization phase is not just right, the risk of ventricular arrhythmia and sudden cardiac death increases significantly.

12 Sep 2011

WSU researcher receives $418,000 NINDS grant to study spinal muscular atrophy

Graham Parker, Ph.D., assistant professor of research in the Department of Pediatrics at Wayne State University's School of Medicine, was awarded $418,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health to study how a particular gene might be involved in the progression of spinal muscular atrophy (SMA) - the number one genetic killer of children younger than 2 years old.

12 Sep 2011

NIH awards $12.8 million renewal grant for Louisville adult stem cell research project

At the time when Dr. Roberto Bolli received word that he was awarded a $12.8 million grant renewal from the National Institutes of Health for one research project, five patients in another of his clinical trials at the University of Louisville have reached the successful endpoint of their participation.

9 Sep 2011

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

9 Sep 2011

Weight Watchers more effective alternative to primary care for obese adults

A new, one-year global study published today in The Lancet indicates that overweight and obese adults referred to Weight Watchers, a community based provider of weight-loss services, lost more than twice as much weight when compared with those who received standard care.

9 Sep 2011

Ohio Third Frontier grants to advance Philips Healthcare Global Advanced Imaging Innovation Center

The Ohio Third Frontier Commission has awarded $2.5 million in research grants to advance the Philips Healthcare Global Advanced Imaging Innovation Center, a collaboration among Case Western Reserve University, University Hospitals (UH) Case Medical Center and Philips Healthcare. The research projects are part of $30 million in funding awarded throughout the State of Ohio this week by the Ohio Third Frontier Commission.

8 Sep 2011

First-ever comprehensive study of species origins of nature-derived drugs

In a first-ever comprehensive study of the species origins of nature-derived drugs, it is shown that drug-producing species are concentrated and clustered in a limited number of families, refuting the conventional view that as every nature species produces biologically active molecules, one can find drugs from almost any major block of species groups if one looks for them hard enough.

8 Sep 2011

Beta-glucans can help wounds to heal quickly

Can wounds be helped to heal faster? Yes, says a Norwegian company whose product's active ingredient, beta-glucans, comes from common baker's yeast.

8 Sep 2011

St. Jude Medical receives approval for CRT-D quadripolar pacing system in India

St. Jude Medical, Inc., a global medical device company, today announced the approval of the industry's first quadripolar pacing system for cardiac resynchronization therapy defibrillators (CRT-Ds) in India. The Promote Quadra CRT-D offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.

7 Sep 2011

Loss of estrogen receptor alpha protein may lead to metabolic syndrome

UCLA researchers demonstrated that loss of a key protein that regulates estrogen and immune activity in the body could lead to aspects of metabolic syndrome, a combination of conditions that can cause Type 2 diabetes, atherosclerosis and cancer. Called estrogen receptor alpha, this protein is critical in regulating immune system activity such as helping cells suppress inflammation and gobble-up debris.

7 Sep 2011

FDA reviews safety issues of bisphosphonates for osteoporosis

An advisory committee for U.S. Food and Drug Administration meets Friday to review the safety of a popular class of osteoporosis drugs called bisphosphonates amid worry that their long-term use could cause rare fractures of the thighbones and affect the jawbone. The committee will evaluate whether women should temporarily stop using the drugs or use them for only a few years.

6 Sep 2011

McMaster team demonstrates essential role of AMPK enzyme in exercise

You may think your lack of resolve to get off the couch to exercise is because you're lazy, but McMaster University researchers have discovered it may be you are missing key genes.

6 Sep 2011

Researchers reveal mechanism behind how cells communicate

Cell communication is essential for the development of any organism. Scientists know that cells have the power to "talk" to one another, sending signals through their membranes in order to "discuss" what kind of cell they will ultimately become - whether a neuron or a hair, bone, or muscle. And because cells continuously multiply, it's easy to imagine a cacophony of communication.

6 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Muscle News and Research

University of Adelaide research focuses on techniques to treat swallowing disorders

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Researchers discover that recognisable facial expressions develop before birth

New treatment strategy for dominant forms of muscular dystrophy

Researchers describe new function of HCN channels in the heart

WSU researcher receives $418,000 NINDS grant to study spinal muscular atrophy

NIH awards $12.8 million renewal grant for Louisville adult stem cell research project

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Weight Watchers more effective alternative to primary care for obese adults

Ohio Third Frontier grants to advance Philips Healthcare Global Advanced Imaging Innovation Center

First-ever comprehensive study of species origins of nature-derived drugs

Beta-glucans can help wounds to heal quickly

St. Jude Medical receives approval for CRT-D quadripolar pacing system in India

Loss of estrogen receptor alpha protein may lead to metabolic syndrome

FDA reviews safety issues of bisphosphonates for osteoporosis

McMaster team demonstrates essential role of AMPK enzyme in exercise

Researchers reveal mechanism behind how cells communicate

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News